Hancock Whitney Corp Catalyst Pharmaceuticals, Inc. Transaction History
Hancock Whitney Corp
- $3.11 Billion
- Q4 2024
A detailed history of Hancock Whitney Corp transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Hancock Whitney Corp holds 38,322 shares of CPRX stock, worth $866,077. This represents 0.03% of its overall portfolio holdings.
Number of Shares
38,322
Previous 38,928
1.56%
Holding current value
$866,077
Previous $773,000
3.36%
% of portfolio
0.03%
Previous 0.03%
Shares
18 transactions
Others Institutions Holding CPRX
# of Institutions
348Shares Held
98.5MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$423 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$191 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$131 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$70.8 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$68.1 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.32B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...